SMSbiotech Receives FDA “Study May Proceed” Notification for First U.S. IND-Cleared Inhaled Stem Cell Therapy in COPD
IND effective following 30-day FDA review; Phase 1b trial expected to initiate in Q4 2026. SMS Cells are the only...
Read moreDetails